ATE519498T1 - Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen - Google Patents

Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen

Info

Publication number: ATE519498T1
Authority: AT; Austria
Prior art keywords: somatostatin; combination; receptor subtypes; analogas; different selectivity
Prior art date: 2006-02-09

Application number

AT07703319T

Other languages

English (en)

Inventor

Herbert Schmid

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-02-09

Filing date

2007-02-07

Publication date

2011-08-15

2007-02-07 Application filed by Novartis Ag filed Critical Novartis Ag

2011-08-15 Application granted granted Critical

2011-08-15 Publication of ATE519498T1 publication Critical patent/ATE519498T1/de

Links

101000632994 Homo sapiens Somatostatin Proteins 0.000 title abstract 2
102000005157 Somatostatin Human genes 0.000 title abstract 2
108010056088 Somatostatin Proteins 0.000 title abstract 2
102000045305 human SST Human genes 0.000 title abstract 2
102000005962 receptors Human genes 0.000 title abstract 2
108020003175 receptors Proteins 0.000 title abstract 2
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 2
229960000553 somatostatin Drugs 0.000 title abstract 2
101000633010 Rattus norvegicus Somatostatin Proteins 0.000 abstract 1
108050001286 Somatostatin Receptor Proteins 0.000 abstract 1
102000011096 Somatostatin receptor Human genes 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000000816 peptidomimetic Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
NHXLMOGPVYXJNR-UHFFFAOYSA-N srif Chemical compound N1C(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(CC=2C3=CC=CC=C3NC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)CNC(=O)C(C)N)CSSCC(C(O)=O)NC(=O)C(CO)NC(=O)C(C(O)C)NC(=O)C1CC1=CC=CC=C1 NHXLMOGPVYXJNR-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)

AT07703319T 2006-02-09 2007-02-07 Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen ATE519498T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0602639.7A GB0602639D0 (en)	2006-02-09	2006-02-09	Organic compounds
PCT/EP2007/001036 WO2007096055A1 (en)	2006-02-09	2007-02-07	Combination of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes

Publications (1)

Publication Number	Publication Date
ATE519498T1 true ATE519498T1 (de)	2011-08-15

Family

ID=36119810

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07703319T ATE519498T1 (de)	2006-02-09	2007-02-07	Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen

Country Status (15)

Country	Link
US (2)	US8450272B2 (de)
EP (1)	EP1988914B1 (de)
JP (1)	JP5189993B2 (de)
KR (1)	KR101466410B1 (de)
CN (1)	CN101378775B (de)
AT (1)	ATE519498T1 (de)
AU (1)	AU2007218297B2 (de)
BR (1)	BRPI0707560B8 (de)
CA (1)	CA2638065C (de)
ES (1)	ES2369155T3 (de)
GB (1)	GB0602639D0 (de)
PL (1)	PL1988914T3 (de)
PT (1)	PT1988914E (de)
RU (1)	RU2451520C2 (de)
WO (1)	WO2007096055A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101245022B1 (ko)	2005-01-21	2013-03-19	카무러스 에이비	약제학적 지질 조성물
GB0602639D0 (en) *	2006-02-09	2006-03-22	Novartis Ag	Organic compounds
WO2010003939A1 (en)	2008-07-08	2010-01-14	Novartis Ag	Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia
BR112014029425A2 (pt) *	2012-05-25	2017-06-27	Camurus Ab	pré-formulação, dispositivo de administração pré-cheio, kit, processo para a formação de uma pré-formulação, usos de mistura e de um solvente polar, e, método para o tratamento de um sujeito
TWI704919B (zh)	2012-05-31	2020-09-21	日商大塚製藥股份有限公司	用於預防及/或治療多囊性腎臟病之藥物
WO2014165607A2 (en) *	2013-04-02	2014-10-09	Stealth Peptides International, Inc.	Aromatic-cationic peptide formulations, compositions and methods of use
JP6869720B2 (ja) *	2013-06-13	2021-05-12	アンチセンスセラピューティクスリミテッド	併用療法
CN120131956A (zh) *	2023-12-11	2025-06-13	中山大学中山眼科中心	生长激素抑制剂的用途、和含有生长激素抑制剂的药物组合物、制剂、及其装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2774591B1 (fr) *	1998-02-12	2000-05-05	Lipha	Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
GB0018891D0 (en) *	2000-08-01	2000-09-20	Novartis Ag	Organic compounds
DE60220157T2 (de) *	2001-03-06	2008-01-17	Il Consorzio Ferrara Richerche	Verfahren zur modulierung der proliferation von medullären schilddrüsen-karzinomzellen
MXPA03012042A (es)	2001-06-25	2006-05-22	Il Consorzio Ferrara Richerche	Composiciones farmaceuticas que inhiben la proliferacion de adenomas pituitarios y metodos de uso de las mismas.
WO2003045320A2 (en) *	2001-11-21	2003-06-05	Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.	Somatostatin analog and uses thereof
WO2005041901A2 (en) *	2003-11-03	2005-05-12	Elixir Pharmaceuticals, Inc.	Therapeutics using somatostatin agonists
US7842654B2 (en) *	2003-12-03	2010-11-30	The Procter & Gamble Company	Method, articles and compositions for cleaning bathroom surfaces
ES2383303T3 (es) *	2005-11-10	2012-06-20	Chemi S.P.A.	Formulaciones de inhibidores de la liberación prolongada de la hormona del crecimiento análogos de la somatostatina
GB0602639D0 (en) *	2006-02-09	2006-03-22	Novartis Ag	Organic compounds

2006
- 2006-02-09 GB GBGB0602639.7A patent/GB0602639D0/en not_active Ceased
2007
- 2007-02-07 PL PL07703319T patent/PL1988914T3/pl unknown
- 2007-02-07 AT AT07703319T patent/ATE519498T1/de active
- 2007-02-07 BR BRPI0707560A patent/BRPI0707560B8/pt active IP Right Grant
- 2007-02-07 ES ES07703319T patent/ES2369155T3/es active Active
- 2007-02-07 PT PT07703319T patent/PT1988914E/pt unknown
- 2007-02-07 US US12/162,715 patent/US8450272B2/en active Active
- 2007-02-07 WO PCT/EP2007/001036 patent/WO2007096055A1/en not_active Ceased
- 2007-02-07 CA CA2638065A patent/CA2638065C/en active Active
- 2007-02-07 KR KR1020087019493A patent/KR101466410B1/ko active Active
- 2007-02-07 CN CN2007800049919A patent/CN101378775B/zh active Active
- 2007-02-07 AU AU2007218297A patent/AU2007218297B2/en active Active
- 2007-02-07 EP EP07703319A patent/EP1988914B1/de active Active
- 2007-02-07 JP JP2008553675A patent/JP5189993B2/ja active Active
- 2007-02-07 RU RU2008136073/15A patent/RU2451520C2/ru active
2013
- 2013-04-30 US US13/873,289 patent/US9149510B2/en active Active

Also Published As

Publication number	Publication date
CA2638065C (en)	2016-03-29
WO2007096055A1 (en)	2007-08-30
JP2009526002A (ja)	2009-07-16
BRPI0707560B8 (pt)	2021-05-25
BRPI0707560A2 (pt)	2011-05-10
BRPI0707560B1 (pt)	2019-06-04
US20130237480A1 (en)	2013-09-12
US20090029910A1 (en)	2009-01-29
GB0602639D0 (en)	2006-03-22
US8450272B2 (en)	2013-05-28
AU2007218297A1 (en)	2007-08-30
EP1988914B1 (de)	2011-08-10
PT1988914E (pt)	2011-10-18
EP1988914A1 (de)	2008-11-12
AU2007218297B2 (en)	2010-09-09
PL1988914T3 (pl)	2012-01-31
CA2638065A1 (en)	2007-08-30
KR20080106896A (ko)	2008-12-09
JP5189993B2 (ja)	2013-04-24
RU2008136073A (ru)	2010-03-20
ES2369155T3 (es)	2011-11-25
US9149510B2 (en)	2015-10-06
RU2451520C2 (ru)	2012-05-27
KR101466410B1 (ko)	2014-11-27
CN101378775A (zh)	2009-03-04
CN101378775B (zh)	2013-06-12

Legal Events

Date

Code

Title

Description

2012-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1988914

Country of ref document: EP

Publication	Publication Date	Title
ATE519498T1 (de)	2011-08-15	Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen
ATE469895T1 (de)	2010-06-15	Cgrp-rezeptorantagonisten
EA201071169A1 (ru)	2011-04-29	ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
NO20092470L (no)	2009-08-27	Substituerte diazepanforbindelser som orexinreseptorantagonister
HN2008001720A (es)	2009-06-10	Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
WO2008021851A3 (en)	2008-06-26	Novel compounds as antagonists or inverse agonists for opioid receptors
DE602007012072D1 (de)	2011-03-03	Orantagonisten
NI201100084A (es)	2011-11-03	Antagonistas del receptor de orexina de isonicotinamida.
CR20130409A (es)	2013-10-17	Novedosos derivados de azabencimidazolcíclico útiles como agentes antidiabéticos
MX384206B (es)	2025-03-14	Formulaciones de inhibidores de dpp iv
CY1110882T1 (el)	2015-06-10	Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης
CL2009000349A1 (es)	2010-02-19	Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
EA201290964A1 (ru)	2013-05-30	Пептидные конъюгаты агонистов рецептора glp-1 и их применение
ATE484505T1 (de)	2010-10-15	5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
ECSP067121A (es)	2007-01-26	3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ATE542795T1 (de)	2012-02-15	Benzylpiperazinderivate als motilin- rezeptorantagonisten
ATE458740T1 (de)	2010-03-15	1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
EA200802104A1 (ru)	2009-04-28	Применение композиций, содержащих антагонисты каппа-опиоидных рецепторов, для лечения диссоциативных расстройств
MA33059B1 (fr)	2012-02-01	Utilisation d'antagonistes des recepteurs nk
BRPI0818450A2 (pt)	2015-05-12	Antagonistas do receptor de 5-ht7
MEP1008A (xx)	2010-02-10	3-aminociklopentankarboksamidi kao modulatori receptora hemokina
MA32224B1 (fr)	2011-04-01	Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
WO2008142319A3 (fr)	2009-02-19	Analogues peptidiques des recepteurs des melanocortines
ATE474834T1 (de)	2010-08-15	Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
ATE525370T1 (de)	2011-10-15	Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten